News | December 06, 2022
Briefs: Natco Pharma & Lupin
Natco Chlorantraniliprole (CTPR) Process does not infringe FMC's Indian Patent 298645.
Natco Chlorantraniliprole (CTPR) Process does not infringe FMC's Indian Patent 298645.
Move to increase affordability and accessibility for heart failure patients across the country
With this QIP placement, the Dhanuka group, which took over the company in 2018, is also meeting its mandatory obligation to dilute 15 percent stake in the company by March 2023
This product is based on Osmotic Controlled Release Oral Delivery System technology
QS-21 in blockbuster Shingles vaccine, first vaccine approved for Malaria, promising RSV phase III candidate, and Covid-19 applications.
Gland Pharma enters into a Put Option Agreement to acquire 100% of Cenexi Group
The Business Undertaking of Watson is engaged in the business of developing, manufacturing, marketing and sale of API.
Fredun received one-year contract worth Rs. 65 crores from a Southeast Asian country for Pharma exports
The pharma laboratory is fully equipped with all the machinery needed to support formulation development, resolve technical challenges, and provide customer demonstrations
In fact, the overall CPHI Pharma Index – a collateralised metric of all major ranking categories – has risen by more than 8%, the largest year-on-year gain in the survey’s six year history
Subscribe To Our Newsletter & Stay Updated
